Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 15/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804992 | 0.91 | GRM4 (0.59) | GRM4EPHX2CYP1A2MEN1NPC1 | |
| SCHEMBL14804999 | 0.89 | EPHX2 (0.60) | GRM4EPHX2CYP1A2MEN1NPC1 | |
| SCHEMBL2234997 | 0.89 | EPHX2 (0.60) | GRM4EPHX2CYP1A2MEN1KMT2A | |
| SCHEMBL14804988 | 0.86 | EPHX2 (0.60) | GRM4EPHX2CYP1A2TDO2KMT2A | |
| SCHEMBL2235367 | 0.85 | GRM4 (0.61) | GRM4EPHX2IDO1TDO2 | |
| SCHEMBL14804995 | 0.83 | EPHX2 (0.60) | GRM4EPHX2CYP1A2MEN1NPC1 | |
| SCHEMBL6922687 | 0.83 | EPHX2 (0.56) | GRM4EPHX2CYP1A2 | |
| SCHEMBL2236658 | 0.83 | EPHX2 (0.60) | GRM4EPHX2MAPT | |
| SCHEMBL2237129 | 0.83 | GRM4 (0.61) | GRM4EPHX2MEN1NPC1LMNA | |
| SCHEMBL6923762 | 0.83 | EPHX2 (0.66) | GRM4EPHX2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916584-B2 | Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2011100614-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRIK4, GRM4, GRIA4 | GRM4 2/4885EPHX2 2498/4885CYP1A2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.